Futibatinib is a special medicine for cholangiocarcinoma patients with FGFR2 fusions. It’s targeted at the FGFR2 protein. You should take 20 mg of Futibatinib by mouth, once each day.
It’s in the form of 4 mg tablets. and is available in bottles containing 28 tablets per package, aiming to disrupt FGFR signaling pathways that contribute to tumor growth and progression in specific cancer patient populations. They’re made so you can take them easily and they work pretty well, giving you a consistent dose.
